any statement that may predict, forecast, indicate, or imply future
results, performance or achievements, and may contain the words "estimate,"
"project," "intend," "forecast," "anticipate," "plan," "planning,"
"expect," "believe," "will," "will likely," "should," "could," "would,"
"may" or words or expressions of similar meaning. All such forward-looking
statements involve risks and uncertainties, including, but not limited to:
statements regarding the Company's products; marketing and sales; patents
and regulatory approvals; the effect of competition and proprietary rights
of third parties; the need for and availability of additional financing and
access to capital; the seeking of joint development, licensing or
distribution and collaboration, marketing arrangements with other companies
and other information detailed from time to time in our filings with the
United States Securities and Exchange Commission. There can be no assurance
that such forward-looking statements will prove to be accurate and Yongye
undertakes no obligation to update any forward-looking statements or to
announce revisions to any of the forward-looking statements.
For more information, please contact:
Yongye Biotechnology International, Inc.
Mr. Larry Gilmore, Principal Financial
Officer & VP of Corporate Strategy
Phone: +86-8232-8866 Ext 8880
CCG Investor Relations, Inc.
Mr. Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
Page: 1 2 3 4 5 6 Related biology technology :1
|SOURCE Yongye Biotechnology International, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market2
. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy3
. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook4
. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter5
. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery6
. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma7
. XTL Receives Staff Letter From NASDAQ8
. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market9
. Pharmos Issues Letter to Shareholders10
. Coherent, Inc. Receives Expected Letter from NASDAQ11
. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA